FrancophonIA/ELRC3.0 huggingface dataset:
English: For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasive fungal infection should be suspected and administration of AMGEVITA should be promptly discontinued.
Croatian: Ako se u bolesnika pojave znakovi i simptomi kao što su vrućica, malaksalost, gubitak težine, znojenje, kašalj, dispneja i/ili plućni infiltrati ili druge ozbiljne sistemske bolesti s istodobnim šokom ili bez njega, treba posumnjati na invazivnu gljivičnu infekciju te odmah prekinuti primjenu lijeka AMGEVITA.
English: Among patients whose adalimumab treatment was withdrawn at week 12 in Studies HS-I and HS-II, the HiSCR rate 12 weeks after re-introduction of adalimumab 40 mg weekly returned to levels similar to that observed before withdrawal (56.0%).
Croatian: Među bolesnicima kojima je liječenje adalimumabom ukinuto nakon 12. tjedna u ispitivanjima HS-I i HS-II, stopa HiSCR-a zabilježena 12 tjedana nakon ponovnog uvođenja adalimumaba u dozi od 40 mg svaki tjedan vratila se na razine slične onima prije prekida liječenja (56,0%).
English: Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis are inflammatory diseases.
Croatian: Poliartikularni juvenilni idiopatski artritis i artritis povezan s entezitisom upalne su bolesti.
English: Uncommon (may affect up to 1 in 100 people) • elevated bilirubin measurement (liver blood test).
Croatian: Manje često (mogu se javiti u do 1 na 100 osoba) • povišena razina bilirubina (vidljivo u nalazima krvne pretrage kojom se provjerava rad jetre).
English: Should treatment be interrupted, AMGEVITA may be re-introduced as appropriate.
Croatian: Ako liječenje treba privremeno prekinuti, AMGEVITA se kasnije po potrebi može ponovno uvesti.
English: Figure 1: Kaplan-Meier Curves Summarising Time to Flare in Study nr-axSpA II
Croatian: Slika 1: Kaplan-Meier-ove krivulje koje sažeto prikazuju vrijeme do pogoršanja u ispitivanju nr-axSpA II
English: Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (see table 29).
Croatian: Rezultati iz obaju ispitivanja pokazali su statistički značajno smanjenje rizika od neuspjeha liječenja u bolesnika liječenih adalimumabom u odnosu na one koji su primali placebo (vidjeti Tablicu 29).
English: The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex) (see section 4.4).
Croatian: Pokrov igle napunjene brizgalice napravljen je od suhe prirodne gume (derivat lateksa) (vidjeti dio 4.4).
English: If you forget to use AMGEVITA
Croatian: Ako ste zaboravili primijeniti lijek AMGEVITA
English: In psoriasis studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at week 16 (see tables 17 and 18).
Croatian: U ispitivanjima Psoriasis Study I i II primarni ishod bio je udio bolesnika u kojih je od početka ispitivanja do 16. tjedna postignut odgovor PASI 75 (vidjeti Tablice 17 i 18).
English: The benefits and risks of continued 40 mg weekly or 80 mg every other week therapy should be carefully reconsidered in a patient with an inadequate response after the increase in dosage (see section 5.1).
Croatian: Potrebno je vrlo pažljivo procijeniti koristi i rizike kontinuiranog liječenja lijekom u dozi 40 mg jednom tjedno ili 80 mg svaki drugi tjedan u bolesnika u kojih nije postignut zadovoljavajući odgovor nakon povećanja doziranja (vidjeti dio 5.1).
English: AMGEVITA contains sodium
Croatian: AMGEVITA sadrži natrij
English: Efficacy responses in placebo-controlled AS study - study I reduction of signs and symptoms
Croatian: Tablica 13. Djelotvornost u placebom kontroliranom ispitivanju kod AS-a - ispitivanje I smanjenje znakova i simptoma
English: Step 4: Finish K. Discard the used pre-filled pen and the yellow cap.
Croatian: Korak 4: Završni korak K. Odložite iskorištenu brizgalicu i žutizatvarač igle.
English: The primary endpoint was the percent change from baseline to week 12 in the number of active joints with arthritis (swelling not due to deformity or joints with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -62.6% (median percent change -88.9%) in patients in the adalimumab group compared to -11.6% (median percent change -50.0%) in patients in the placebo group.
Croatian: Primarna mjera ishoda bio je postotak promjene početne vrijednosti do 12. tjedna u broju aktivnih zglobova s artritisom (oticanje koje nije posljedica deformacije ili zglobovi s gubitkom pokretljivosti uz bol i/ili osjetljivost), koji je postignut uz srednji postotak smanjenja od -62,6% (medijan postotka promjene -88,9%) u bolesnika u skupini liječenoj adalimumbom u usporedbi s -11,6% (medijan postotka promjene -50,0%) u bolesnika u skupini koja je primala placebo.
English: Grab the syringe barrel to remove the syringe from the tray.
Croatian: Uhvatite spremnik štrcaljke kako biste izvadili štrcaljku iz podloge.
English: Radiographic mean changes over 12 months in RA study III
Croatian: Tablica 9. Srednje vrijednosti promjena radioloških nalaza tijekom 12 mjeseci u ispitivanju RA III
English: In the post-marketing setting, cases of leukaemia have been reported in patients treated with a TNF-antagonist.
Croatian: Nakon stavljanja lijeka u promet prijavljeni su slučajevi leukemije u bolesnika liječenih antagonistima TNF-a.
English: CD study II: infliximab experienced patients
Croatian: Ispitivanje CD II: bolesnici koji su uzimali infliksimab
English: If you experience allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling or rash do not inject more AMGEVITA and contact your doctor immediately since, in rare cases, these reactions can be life threatening.
Croatian: • Razvijete li alergijske reakcije sa simptomima poput stezanja u prsnom košu, ''piskanja pri disanju'', omaglice, oticanja ili osipa, prestanite ubrizgavati lijek AMGEVITA i odmah se javite liječniku, jer te reakcije u rijetkim slučajevima mogu biti opasne po život.
English: Each pack contains 1, 2, 4 or 6 single use SureClick pre-filled pens.
Croatian: Svako pakiranje sadrži 1, 2, 4 ili 6 SureClick napunjenih brizgalica za jednokratnu primjenu.
English: AMGEVITA may have a minor influence on the ability to drive and use machines.
Croatian: AMGEVITA može imati mali utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
English: In patients who develop HBV reactivation, AMGEVITA should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.
Croatian: U bolesnika u kojih se javi reaktivacija HBV infekcije mora se prekinuti terapija lijekom AMGEVITA i započeti učinkovita antivirusna terapija uz odgovarajuće potporne mjere.
English: • AMGEVITA can be used during breast-feeding.
Croatian: • AMGEVITA se može primjenjivati tijekom dojenja.
English: ● Put the used AMGEVITA syringe in a sharps disposal container immediately after use.
Croatian: Odložite iskorištenu AMGEVITA štrcaljku u spremnik za odlaganje oštrog otpada odmah nakon upotrebe.
English: ● Do not reuse the used syringe.
Croatian: Nemojte ponovno upotrebljavati iskorištenu štrcaljku.
English: *P < 0.05, ***P < 0.001, adalimumab versus placebo a Among all randomised patients b Among patients with baseline HS-related skin pain assessment ≥ 3, based on Numeric Rating Scale 0 - 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine
Croatian: * P < 0,05, ***P < 0,001, adalimumab naspram placebo a Među svim randomiziranim bolesnicima b Među bolesnicima s procijenjenom početnom kožnom boli uzrokovanom gnojnim hidradenitisom ≥ 3 prema brojčanoj ocjenskoj ljestvici od 0 - 10; 0 = bez kožne boli, 10 = nezamislivo jaka kožna bol
English: JSNd score a methotrexate b 95% confidence intervals for the differences in change scores between methotrexate and adalimumab c Based on rank analysis d Joint Space Narrowing
Croatian: a metotreksat b 95%-tni interval pouzdanosti za razliku u promjeni rezultata između metotreksata i adalimumaba c na osnovi analize ranga d suženje zglobnih prostora (eng.
English: Adalimumab demonstrated a treatment benefit in nail psoriasis patients with different extents of skin involvement (BSA ≥ 10% (60% of patients) and BSA < 10% and ≥ 5% (40% of patients)).
Croatian: Adalimumab je ostvario povoljan terapijski učinak u bolesnika s psorijazom noktiju i različitim stupnjevima zahvaćenosti kože (≥ 10% tjelesne površine [60% bolesnika] te < 10% i ≥ 5% tjelesne površine [40% bolesnika]).
English: AMGEVITA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.
Croatian: AMGEVITA je indicirana za liječenje umjerene do teške kronične plak psorijaze u odraslih bolesnika koji su kandidati za sistemsko liječenje.
English: By Week 68, patients receiving continuous adalimumab treatment showed statistically significant greater improvement of the signs and symptoms of active nr-axSpA as compared to patients allocated to treatment withdrawal during the double-blind period of the study (table 15).
Croatian: Do 68. tjedna bolesnici koji su primali kontinuirano liječenje adalimumabom pokazali su statistički značajno veće poboljšanje znakova i simptoma aktivnog nr-axSpA u usporedbi s bolesnicima kojima je bio određen prekid liječenja tijekom dvostruko slijepog razdoblja ispitivanja (Tablica 15).
English: As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check you for signs and symptoms of tuberculosis before starting AMGEVITA.
Croatian: • Budući da su u bolesnika liječenih adalimumabom prijavljeni slučajevi tuberkuloze, prije nego počnete s liječenjem lijekom AMGEVITA, liječnik će provjeriti imate li znakove i simptome tuberkuloze.
English: AMGEVITA reduces the rate of progression of joint damage as measured by x-ray and improves physical function, when given in combination with methotrexate.
Croatian: AMGEVITA smanjuje brzinu progresije oštećenja zglobova mjerene radiološki i poboljšava fizičku funkciju kada se uzima u kombinaciji s metotreksatom.
English: All patients received a 2 week standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by week 15.
Croatian: Svi su bolesnici pri uključivanju u ispitivanje 2 tjedna primali standardiziranu dozu prednizona od 60 mg/dan, nakon čega je uslijedilo obavezno postupno smanjivanje doze, uz potpuni prestanak primjene kortikosteroida do 15. tjedna.
English: Prescribers should exercise caution in considering the use of AMGEVITA in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of AMGEVITA should be considered if any of these disorders develop.
Croatian: Propisivači moraju biti oprezni prilikom razmatranja liječenja lijekom AMGEVITA u bolesnika s otprije postojećim ili nedavno nastalim demijelinizirajućim poremećajima središnjeg ili perifernog živčanog sustava; ako se razvije bilo koji od tih poremećaja, treba razmotriti prekid liječenja lijekom AMGEVITA.
English: After week 2, patients in both adalimumab arms received 40 mg every other week.
Croatian: Nakon drugog tjedna, bolesnici u obje skupine liječene adalimumabom primali su 40 mg svaki drugi tjedan.
English: Efficacy response in placebo-controlled Study nr-axSpA I Double-Blind Response at week
Croatian: Djelotvornost u placebom kontroliranom ispitivanju nr-axSpA I Dvostruko slijepo, odgovor u 12. tjednu
English: The observed rate of nonmelanoma skin cancers is approximately 9.6 per 1,000 patient-years, and the observed rate of lymphomas is approximately 1.3 per 1,000 patient-years.
Croatian: Primijećena stopa nemelanomskih tumora kože je približno 9,6 na 1000 bolesnik-godina, a limfoma 1,3 na 1000 bolesnikgodina.
English: A risk for the development of hepatosplenic T-cell lymphoma in patients treated with AMGEVITA cannot be excluded (see section 4.8).
Croatian: Rizik od pojave hepatospleničnog T-staničnog limfoma u bolesnika liječenih lijekom AMGEVITA ne može se isključiti (vidjeti dio 4.8).
English: Statistically and clinically significant improvements from baseline were also observed in both treatment groups for quality of life parameters (including IMPACT III).
Croatian: Također su u obje skupine u odnosu na početne vrijednosti zabilježena statistički i klinički značajna poboljšanja parametara kvalitete života (uključujući IMPACT III).
English: Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II
Croatian: Djelotvornost u placebom kontroliranom razdoblju za ispitivanje nr-axSpA II
English: CD study I and CD study II induction of remission and response rates are presented in table 23.
Croatian: Indukcija remisije i stopa kliničkog odgovora u ispitivanjima CD I i II nalaze se u Tablici 23.
English: When combining controlled portions of these trials and ongoing and completed open-label extension studies of adalimumab, with a median duration of approximately 3.3 years including 6,427 patients and over 26,439 patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin cancers is approximately 8.5 per 1,000 patient-years.
Croatian: Kada se objedine rezultati kontroliranih dijelova tih ispitivanja te otvorenih produžetaka ispitivanja adalimumaba koji su u tijeku ili dovršeni, s ukupno 6427 bolesnika i više od 26 439 bolesnik-godina terapije te medijanom trajanja od 3,3 godine, primijećena stopa zloćudnih bolesti, isključujući limfome i nemelanomske tumore kože, iznosi približno 8,5 na 1000 bolesnik-godina.
English: Reports of serious allergic reactions including anaphylaxis have been received following adalimumab administration.
Croatian: Ozbiljne alergijske reakcije, uključujući anafilaksiju, prijavljivane su nakon primjene adalimumaba.
English: Polyarticular juvenile idiopathic arthritis from 2 years of age The recommended dose of AMGEVITA for patients with polyarticular juvenile idiopathic arthritis, from 2 years of age is based on body weight (table 1).
Croatian: Poliartikularni juvenilni idiopatski artritis u dobi od 2 godine Preporučena doza lijeka AMGEVITA za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi od 2 godine i starije određuje se na temelju tjelesne težine (Tablica 1).
English: On a clean, well-lit work surface, place a new, pre-filled pen.
Croatian: Na čistu i dobro osvijetljenu radnu površinu položite novu napunjenu brizgalicu.
English: Time to treatment failure at or after week 2 in study UV II Primary analysis (ITT)
Croatian: Vrijeme do neuspjeha liječenja u 2. tjednu ili nakon njega u ispitivanju UV II Primarna analiza (ITT)
English: Ps study II (CHAMPION) efficacy results at 16 weeks Placebo N = 53 n (%)
Croatian: Tablica 17. Ispitivanje Ps I (REVEAL) - rezultati djelotvornosti nakon 16 tjedana Placebo N = 398 n (%)
English: Make sure the medicine in the syringe is clear and colourless to slightly yellow.
Croatian: Provjerite da je lijek u štrcaljki bistar i bezbojan do blago žućkaste boje.
English: In subjects treated with adalimumab with no radiographic progression from baseline to week 48 (n = 102), 84% continued to show no radiographic progression through 144 weeks of treatment.
Croatian: 84% ispitanika liječenih adalimumabom koji nisu imali radiološku progresiju od početka ispitivanja do 48. tjedna ispitivanja (n = 102) nisu imali radiološku progresiju bolesti ni nakon 144 tjedna terapije.
English: The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause allergic reactions.
Croatian: Pokrov igle napunjene brizgalice je napravljen od suhe prirodne gume (derivat lateksa) koja može uzrokovati alergijske reakcije.
English: ● Do not use an AMGEVITA pre-filled syringe if it has been dropped on a hard surface.
Croatian: Nemojte koristiti AMGEVITA napunjenu štrcaljku ako je pala na tvrdu površinu.
English: Both studies demonstrated an early and sustained effect of adalimumab on the treatment failure rate versus placebo (see figure 2).
Croatian: Oba su ispitivanja pokazala rani i održan učinak adalimumaba na stopu neuspjeha liječenja u odnosu na placebo (vidjeti Sliku 2).
English: Adverse Reaction unspecified (including cysts and polyps)*
Croatian: Dobroćudne, zloćudne i nespecificiran e novotvorine (uključujući ciste i polipe)*
English: In psoriasis study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at week 33 compared to 5% continuing on adalimumab, p < 0.001, experienced “loss of adequate response” (PASI score after week 33 and on or before week 52 that resulted in a < PASI 50 response relative to baseline with a minimum of a 6-point increase in PASI score relative to week 33).
Croatian: U ispitivanju Psoriasis Study I, u 28% bolesnika s odgovorom PASI 75 kojima je nakon 33. tjedna pri ponovnoj randomizaciji dodijeljen placebo, u usporedbi s 5% bolesnika koji su nastavili uzimati adalimumab (p < 0,001), uočen je „gubitak primjerenog odgovora“ (PASI rezultat nakon 33. i u ili prije 52. tjedna koji je rezultirao odgovorom < PASI 50 u odnosu na početak terapije, uz porast PASI rezultata za najmanje 6 bodova u odnosu na 33. tjedan).
English: Patients induced with 160/80 mg adalimumab achieved clinical remission versus placebo at week 8 in statistically significantly greater percentages in study UC-I (18% versus 9% respectively, p = 0.031) and study UC-II (17% versus 9% respectively, p = 0.019).
Croatian: Bolesnici koji su primili indukciju adalimumabom u dozi od 160/80 mg u osmom su tjednu postigli kliničku remisiju u značajno većem postotku u odnosu na placebo i u ispitivanju UC-I (18%, odnosno 9%, p = 0,031) i u ispitivanju UC-II (17%, odnosno 9%, p = 0,019).
English: Amongst those who responded (paediatric ACR 30) at week 24 (n = 27 out of 30 patients), the paediatric ACR 30 responses were maintained for up to 60 weeks in the OLE phase in patients who received adalimumab throughout this time period.
Croatian: Među onima koji su odgovorili na terapiju (pedijatrijski odgovor ACR 30) u 24. tjednu (n = 27 od 30 bolesnika), pedijatrijski odgovori ACR 30 održali su se do 60 tjedana u otvorenom produžetku ispitivanja u bolesnika koji su primali adalimumab kroz ovo vremensko razdoblje.
English: Note: P# = Placebo (number of events/number at risk); A# = Adalimumab (number of events/number at risk).
Croatian: Napomena: P# = Placebo (broj događaja/broj bolesnika pod rizikom); A# = Adalimumab (broj događaja/broj bolesnika pod rizikom).
English: Taking these results into consideration, adalimumab is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2).
Croatian: Uzevši to u obzir, preporučuje se da se adalimumab daje u kombinaciji s metotreksatom, a monoterapija samo u onih bolesnika u kojih primjena metotreksata nije prikladna (vidjeti dio 4.2).
English: Percent change in total fingernail NAPSI (%)
Croatian: Postotna promjena ukupnog NAPSI rezultata za psorijazu noktiju na rukama (%)
English: ● Do not put the yellow cap back onto the pre-filled pen.
Croatian: Nemojte vraćati žuti zatvarač natrag na napunjenu brizgalicu.
English: ● Do not put the pre-filled pen back in the refrigerator once it has reached room temperature.
Croatian: Ne vraćajte napunjenu brizgalicu natrag u hladnjak nakonšto je dosegnula sobnu temperaturu.
English: Two weeks later (day 29) continue with a dose of 40 mg every week or 80 mg every other week (given as two 40 mg injections in one day).
Croatian: Dva tjedna kasnije (29. dan) liječenje se nastavlja dozom od 40 mg svaki tjedan ili 80 mg svaki drugi tjedan (primijenjena kao dvije injekcije od 40 mg u jednom danu).
English: b 2-sided P value from log rank test. c NE = not estimable.
Croatian: b Dvostrana P-vrijednost iz log rang testa.
English: Week 2 Week 12 Week 24 ***, ** Statistically significant at p < 0.001, < 0.01 for all comparisons between adalimumab and placebo at weeks 2, 12 and 24 a Assessments in Ankylosing Spondylitis b Bath Ankylosing Spondylitis Disease Activity Index
Croatian: 2. tjedan 12. tjedan 24. tjedan ***, **Statistički značajno uz p < 0,001, p < 0,01 za sve usporedbe adalimumaba s placebom u 2., 12. i 24. tjednu a Procjena kod ankilozantnog spondilitisa (engl.
English: Important: Always keep the sharps disposal container out of the sight and reach of children.
Croatian: Važno: Čuvajte spremnik za odlaganje oštrog otpada daleko od pogleda i dohvata djece.
English: Patients were then retreated with adalimumab 0.8 mg/kg every other week for an additional 16 weeks and response rates observed during retreatment were similar to the previous double-blind period: PASI 75 response of 78.9% (15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).
Croatian: Bolesnici su zatim ponovno započeli liječenje adalimumabom u dozi od 0,8 mg/kg svaki drugi tjedan tijekom dodatnih 16 tjedana, a stope odgovora primijećene tijekom ponovnog liječenja bile su slične onima prethodno zabilježenima tijekom razdoblja dvostruko slijepog liječenja: odgovor PASI 75 postiglo je 78,9% (15 od 19 ispitanika), a PGA rezultat 'bez bolesti' ili 'minimalno' njih 52,6% (10 od 19 ispitanika).
English: Time to treatment failure at or after week 6 in study UV I Primary analysis (ITT)
Croatian: Vrijeme do neuspjeha liječenja u 6. tjednu ili nakon njega u ispitivanju UV I Primarna analiza (ITT)
English: Clinical response is usually achieved within 12 weeks of treatment.
Croatian: Klinički odgovor obično se postiže unutar 12 tjedana liječenja.
English: ● Do not recycle the syringe or sharps disposal container or throw them into the household waste.
Croatian: Nemojte reciklirati štrcaljke niti spremnik za odlaganje oštrog otpada ili ih bacati u kućni otpad.
English: Subjects (n = 215, 54.7%) who failed to achieve ASAS 20 at weeks 12, or 16 or 20 received early escape open-label adalimumab 40 mg every other week subcutaneously and were subsequently treated as non-responders in the double-blind statistical analyses.
Croatian: Ispitanici (n = 215, 54,7%) koji nisu uspjeli postići ASAS 20 u 12., 16. ili 20. tjednu ranije su prebačeni u otvoreni dio ispitivanja i dobivali su 40 mg adalimumaba supkutano svaki drugi tjedan.
English: Tell your doctor if you are taking azathioprine or 6-mercaptopurine with AMGEVITA.
Croatian: Obavijestite liječnika ako istodobno uz lijek AMGEVITA uzimate azatioprin ili 6-merkaptopurin.
English: In addition, no malignancies were observed in 192 paediatric patients with an exposure of 498.1 patient-years during an adalimumab trial in paediatric patients with Crohn's disease.
Croatian: Dodatno, nisu primijećene zloćudne bolesti u 192 pedijatrijska bolesnika s izloženošću od 498,1 bolesnik-godina u ispitivanjima adalimumaba u pedijatrijskih bolesnika s Crohnovom bolešću.
English: AMGEVITA can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).
Croatian: AMGEVITA se može primjenjivati istodobno s metotreksatom ili nekim antireumaticima koji mijenjaju tijek bolesti (sulfasalazinom, hidroksiklorokinom, leflunomidom i injekcijskim pripravcima zlata), steroidima ili analgeticima, uključujući i nesteroidne protuupalne lijekove (NSAIL).
English: Maintenance of remission and response rates are presented in table 24.
Croatian: Održavanje remisije i stope kliničkog odgovora nalaze se u Tablici 24.
English: - The needle cap is missing or not securely attached.
Croatian: - Nedostaje zatvarač igle ili nije dobro pričvršćen.